Cargando…

903. A Real-world Study Assessing the Risk of Lipid Changes and Other Metabolic Effects Associated with Integrase Inhibitor-based Antiretroviral Therapy

BACKGROUND: Integrase inhibitor (INSTI)-based antiretroviral therapies (ART) are first-line for HIV infection. Recent studies have identified metabolic complications of INSTI regimens, especially when TAF is included. The objective of this study was to assess lipid changes associated with INSTI-base...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gruss, Zachary, Stone, Tyler, Johnson, James, Morse, Caryn, Williamson, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644265/ http://dx.doi.org/10.1093/ofid/ofab466.1098

Ejemplares similares

KDP 903
por: KEK. Tsukuba
Publicado: (1992)

903. SSI Trends in Community Hospitals from 2013 to 2018
por: Seidelman, Jessica L, et al.
Publicado: (2020)

P903: CLINICAL UTILITY OF MONOCLONAL GAMMOPATHY SCREENING IN THE EVALUATION OF PERIPHERAL NEUROPATHY
por: Maberry, Mackenzie, et al.
Publicado: (2023)

889. Early Discontinuations and Adverse Events Among Treatment-Naïve Patients Initiating Integrase Inhibitors in a Real-world Setting
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2021)

Integrase inhibitor-based treatment in clinical practice
por: Cenderello, G, et al.
Publicado: (2010)

Impact of the HIV integrase genetic context on the phenotypic expression and in vivo dynamics of integrase inhibitor resistance mutations
por: Nguyen, Nga, et al.
Publicado: (2013)

Resistance to new antiretrovirals (ETV, anti-integrases, entry inhibitors)
por: Ceccherini-Silberstein, Francesca
Publicado: (2010)

614. Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2021)

1049. Weight Gain in Persons Living with HIV (PLWH) Treated with Bictegravir Compared to Other Integrase Strand Transfer Inhibitors
por: Fang, Michelle, et al.
Publicado: (2020)

Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium
por: Byonanebye, Dathan M., et al.
Publicado: (2022)

Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
por: Santos, José Ramón, et al.
Publicado: (2023)

Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors
por: Alejos, Belén, et al.
Publicado: (2019)

1005. Comparison of Weight Changes in Treatment-Naïve, HIV-Infected Patients Receiving Integrase Inhibitor-Based Therapy Versus Protease Inhibitor-Based Therapy
por: Howe, Zachary, et al.
Publicado: (2020)

Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium
por: Neesgaard, Bastian, et al.
Publicado: (2020)

2060. Evaluation of the real world incidence of integrase inhibitor resistance since adoption as guideline preferred therapy
por: Januszka, Jenna, et al.
Publicado: (2022)

Differences in Apoptosis and Cell Cycle Distribution between Human Melanoma Cell Lines UACC903 and UACC903(+6), before and after UV Irradiation
por: Zhang, Qiuyang, et al.
Publicado: (2007)

P903: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE IN NEWLY DIAGNOSED PATIENTS WITH MAYO 2004 STAGE 3 LIGHT-CHAIN AMYLOIDOSIS: A PROSPECTIVE PHASE 2 STUDY
por: Gao, Y.-J., et al.
Publicado: (2022)

946. Risk factors and Metabolic Implications of Integrase Inhibitor Associated Weight Gain
por: Asundi, Archana, et al.
Publicado: (2020)

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?
por: Vogel, Martin, et al.
Publicado: (2009)

The impact of integrase inhibitors on steatosis and fibrosis biomarkers in persons with HIV naïve to antiretroviral therapy
por: Fernandes, Sara Rodrigues, et al.
Publicado: (2023)

Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in Germany
por: Meixenberger, Karolin, et al.
Publicado: (2014)

Correction to Lancet Infect Dis 2019; 19: 903–12
Publicado: (2020)

Real-World Assessment of Weight Change in People with HIV-1 After Initiating Integrase Strand Transfer Inhibitors or Protease Inhibitors
por: Chen, Yen-Wen, et al.
Publicado: (2020)

Docking studies of flavonoid derivatives as potent HIV-1 integrase inhibitors
por: Premjanu, N, et al.
Publicado: (2014)

Resistance to Integrase Inhibitors
por: Métifiot, Mathieu, et al.
Publicado: (2010)

Novel 3′-Processing Integrase Activity Assay by Real-Time PCR for Screening and Identification of HIV-1 Integrase Inhibitors
por: Sakkhachornphop, Supachai, et al.
Publicado: (2015)

Molecular mechanism underlying differential apoptosis between human melanoma cell lines UACC903 and UACC903(+6) revealed by mitochondria-focused cDNA microarrays
por: Zhang, Qiuyang, et al.
Publicado: (2008)

Risk of immune reconstitution inflammatory syndrome with integrase inhibitors versus other classes of antiretrovirals: a systematic review and meta-analysis of randomised trials
por: Zhao, Ying, et al.
Publicado: (2022)

A targeted DNA substrate mechanism for the inhibition of HIV‐1 integrase by inhibitors with antiretroviral activity
por: Ammar, Farah F., et al.
Publicado: (2016)

Altered adipose tissue macrophage populations in people with HIV on integrase inhibitor-containing antiretroviral therapy
por: Vakili, Sarah, et al.
Publicado: (2022)

Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors
por: Rhee, Soo-Yon, et al.
Publicado: (2008)

Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy
por: McCausland, Marie R., et al.
Publicado: (2015)

The potential impact of initiating antiretroviral therapy with integrase inhibitors on HIV transmission risk in British Columbia, Canada
por: Zhu, Jielin, et al.
Publicado: (2019)

334. Weight Change Associated with Antiretroviral Therapy Switch to Integrase Strand Transfer Inhibitor-Based Regimens
por: Saber, Saghar, et al.
Publicado: (2019)

Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor–Based Antiretroviral Treatment
por: Pyngottu, Ashima, et al.
Publicado: (2020)

Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy
por: Surial, Bernard, et al.
Publicado: (2023)

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study
por: Underwood, Mark, et al.
Publicado: (2022)

A Cautionary Tale: Tn903 aph, Kanamycin Resistance Redux in the Environment
por: Miao, Vivian P. W.
Publicado: (2017)

SUN-903 Insulinoma - a Tricker Diagnosis When Some Pieces Are Missing
por: Silva, Maria Manuel
Publicado: (2020)

Relationship between HIV integrase polymorphisms and integrase inhibitor susceptibility: An in silico analysis
por: Hutapea, Hotma Martogi Lorensi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vekl7le9d4ne1h6fvk7s4oes92